Trial Profile
A PHASE III, MULTI-CENTER, RANDOMIZED OPEN LABEL STUDY OF VELCADE, MELPHALAN, PREDNISONE AND THALIDOMIDE (V-MPT) Versus VELCADE, MELPHALAN, PREDNISONE (V-MP) IN ELDERLY UNTREATED MULTIPLE MYELOMA PATIENTS.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Aspirin; Enoxaparin sodium; Melphalan; Prednisone; Thalidomide; Warfarin
- Indications Multiple myeloma
- Focus Therapeutic Use
- 21 Jun 2020 Results of network meta-analysis (NMA) assessing the efficacy of some different maintenance and continuous regimens in MM treatment presented at the 25th Congress of the European Haematology Association
- 12 Dec 2017 Results of a subanalysis from Gimema-MM-03-05 and EMN01 studies, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 09 May 2016 Status changed from active, no longer recruiting to completed.